Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
March 30, 2015 at 08:01 AM EDT
Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, ...